Genta Genasense Fails To Demonstrate “Any Clinical Benefit” Improvements, FDA Tells Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
Latest supplement to support a venous thromboembolism indication for Pfizer’s Fragmin will also be discussed by Oncologic Drugs Advisory Committee Sept. 6.